Similar trials were designed to treat RDEB, but a significant obstacle has been the large size of the COL7A1 gene, which has a negative impact on viral gene therapy vectors, limiting manufacture and transduction efficiency [25]. This evidence concerns the gene COL7A1 and recessive dystrophic epidermolysis bullosa.